Top

Strahlentherapie und Onkologie

Published in:

01-07-2015 | Literatur kommentiert

Effekt der additiven Boost-Bestrahlung bei der Radiotherapie nach brusterhaltender Operation des frühen Mammakarzinoms

20-Jahres-Daten der EORTC-Studie

Authors: Kirsten Eilf, Prof. Dr. Jürgen Dunst

Published in: Strahlentherapie und Onkologie | Issue 7/2015

Auszug

Die Boost-Bestrahlung ist Standard in der adjuvanten Therapie des Mammakarzinoms nach brusterhaltender Operation. Die wichtigsten Daten dazu stammen aus der großen EORTC-Studie, deren Ergebnisse jetzt erneut mit einem Follow-up von 20 Jahren publiziert wurden [3]. …

Bartelink H, Horiot JC, Poortmans P et al (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378–1387PubMedCrossRef

Bartelink H, Horiot JC, Poortmans PM et al (2007) Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol 25:3259–3265PubMedCrossRef

Bartelink H, Maingon P, Poortmans P et al (2015) Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16:47–56PubMedCrossRef

Collette S, Collette L, Budiharto T et al (2008) Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer a study based on the EORTC trial 22881–10882 ‘boost versus no boost’. Eur J Cancer 44:2587–2599PubMedCrossRef

Immink JM, Putter H, Bartelink H et al (2012) Long-term cosmetic changes after breast-conserving treatment of patients with stage I–II breast cancer and included in the EORTC ‘boost versus no boost’ trial. Ann Oncol 23:2591–2598PubMedCrossRef

Poortmans PM, Collette L, Horiot JC Radiation Oncology and Breast Cancer Groups et al (2009) Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol 90:80–85PubMedCrossRef

Romestaing P, Lehingue Y, Carrie C et al (1997) Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963–968PubMed

Title: Effekt der additiven Boost-Bestrahlung bei der Radiotherapie nach brusterhaltender Operation des frühen Mammakarzinoms
20-Jahres-Daten der EORTC-Studie
Authors: Kirsten Eilf
Prof. Dr. Jürgen Dunst
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 7/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0844-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effekt der additiven Boost-Bestrahlung bei der Radiotherapie nach brusterhaltender Operation des frühen Mammakarzinoms

20-Jahres-Daten der EORTC-Studie

Auszug

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 7/2015

Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma

Impact of flattening-filter-free radiation on the clonogenic survival of astrocytic cell lines

Information preferences regarding cure rates and prognosis of Austrian patients with advanced lung cancer

High-grade acute organ toxicity and p16INK4A expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma

Long-term side effects of radiotherapy for pediatric localized neuroblastoma

Sollte man nach brusterhaltender Therapie bei Frauen über 65 Jahren mit einem frühen Mammakarzinom auf die adjuvante Radiotherapie verzichten?